Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Neoplasms × niraparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 2 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Neoplasms 1 Metastatic Castration-sensitive Prostate Cancer 1

Interventions

trametinib 3 encorafenib 3 dabrafenib 3 Oxaliplatin 3 zolbetuximab 2 selpercatinib 2 pembrolizumab 2 lenvatinib 2 larotrectinib 2 binimetinib 2 Leucovorin 2 Fulvestrant 2 Fluorouracil 2 Cetuximab 2 Capecitabine 2 trastuzumab deruxtecan 1 tepotinib 1 telisotuzumab vedotin 1 ribociclib 1 repotrectinib 1 relatlimab 1 pralsetinib 1 pegaspargase 1 niraparib 1 dostarlimab 1 blinatumomab 1 avelumab 1 asparaginase erwinia chrysanthemi recombinant 1 adagrasib 1 Vemurafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡